GT Biopharma, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021; filed March 28, 2022. This is an annual report, not a standalone fourth-quarter report.
Business context
GT Biopharma is a clinical-stage biopharmaceutical company developing TriKE immune-cell engager therapies intended to direct and activate natural killer cells against cancers and infected cells. It had no approved products and generated no product revenue in 2021. Its lead Phase 1 candidate, GTB-3550, completed enrollment in September 2021; the company is shifting development to next-generation candidates GTB-3650 and GTB-5550.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.6 million | $0.5 million |
| Selling, general and administrative expense | $47.9 million | $6.3 million |
| Operating loss | $57.5 million | $6.8 million |
| Net loss | $58.0 million | $28.3 million |
| Net loss per share | $2.06 | $6.45 |
| Cash used in operating activities | $15.6 million | $7.3 million |
| Cash and short-term investments at year-end | $32.0 million | $5.3 million |
| Total current liabilities at year-end | $10.3 million | $35.1 million |
Margins are not meaningful because the company had no revenue. Year-end cash and investments comprised $9.0 million of cash and cash equivalents and $23.0 million of short-term investments. The balance sheet showed $21.9 million of working capital by calculation; management separately stated working capital of $22.9 million, a difference to verify.
Convertible notes and accrued interest totaling $38.8 million converted into common stock in February 2021. No convertible notes remained at year-end; a $31,000 line-of-credit balance remained. Stock-based compensation was a major expense: the filing reports approximately $33.9 million for the year, materially affecting the reported loss but not representing operating cash outflow.
Changes versus 2020
- Net loss more than doubled, principally as operating expenses increased, including significant stock-based compensation and higher research and development activity.
- R&D expense increased to $9.6 million from $0.5 million, while SG&A rose to $47.9 million from $6.3 million. The company attributed much of the SG&A increase to stock compensation and public-company costs.
- Cash and investments increased following a February public offering that raised $24.7 million net and warrant exercises that generated $16.4 million. The company also raised $1.2 million through convertible notes before their conversion.
- Interest expense fell to $0.7 million from $3.0 million after the notes converted. Prior-year expenses included $12.6 million related to a forbearance agreement and $5.4 million of legal settlement losses; neither was recorded in 2021.
Outlook, risks and unusual items
- Liquidity: Management said $32.0 million of cash and investments should fund operations for at least 12 months from issuance of the financial statements, while also anticipating additional fundraising in 2022. The company has a history of losses, an accumulated deficit of $653.6 million, and expects further losses; continued operations depend on capital availability.
- Planned spending and development: Management estimated 2022 R&D spending of approximately $12–$14 million. It planned to seek an IND for GTB-3650 in the second half of 2022, and to seek an IND for GTB-5550 in the second half of 2022 with a Phase 1 start targeted for the first half of 2023. These are forward-looking plans, not reported outcomes.
- GTB-3550 trial: Twelve patients received escalating doses. The company reported that treatment was generally well tolerated, with no serious cytokine release syndrome cases; four patients had transient reductions in bone marrow leukemic blasts. These early results do not establish efficacy. GTB-3550 will not undergo further clinical development, as the company intends to advance next-generation candidates.
- Manufacturing commitments: The company relies on third parties and has no long-term manufacturing commitment or alternate supplier. Contract-manufacturing commitments were approximately $13.0 million at year-end, including $5.5 million in process for 2022. A University of Minnesota research agreement totals $2.1 million.
- Internal controls and governance: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2021, citing inadequate segregation of duties, executive-override risk, and insufficient accounting policies and procedures. The company disclosed a former CEO’s undocumented, unapproved $2.6 million advance, repaid in full during 2021, and possible issuance of up to 187,500 shares without supporting documentation or board approval. A forensic review was ongoing.
- Legal matters: A $425,000 settlement of the Lion/Vallera litigation was reached in February 2022 and paid in March; the amount had been accrued at year-end. A separate $100,000 lease dispute settlement was paid in August 2021.
- Other risks: The business remains dependent on clinical and regulatory success, external financing, third-party manufacturing, intellectual-property protection, and retention of qualified staff. COVID-19 affected 2021 operations, but the company reported no related asset impairment. Management said the financial statements were prepared on a going-concern basis.
Investor facts to verify
- Reconcile the filing’s $22.9 million working-capital statement with the approximately $21.9 million implied by the year-end balance sheet.
- Track actual cash burn, financing proceeds, and the timing and terms of any additional capital raises against the stated 12-month liquidity expectation.
- Verify progress and timing for GTB-3650 and GTB-5550 IND submissions, clinical starts, and manufacturing readiness.
- Review follow-up disclosures on the forensic accounting review, remediation of material weaknesses, and the undocumented transactions and share issuances.
- Monitor manufacturing commitments, accrued vendor balances, and whether alternative supply arrangements are secured.